Holen Sie sich die Stockscreener-App
2.20
6.28%
0.13
Handel nachbörslich:
2.18
-0.02
-0.91%
Schlusskurs vom Vortag:
$2.07
Offen:
$2.04
24-Stunden-Volumen:
4.72M
Relative Volume:
0.68
Marktkapitalisierung:
$396.19M
Einnahmen:
$850.00K
Nettoeinkommen (Verlust:
$-68.17M
KGV:
-5.345
EPS:
-0.4116
Netto-Cashflow:
$-53.29M
1W Leistung:
+21.55%
1M Leistung:
-56.26%
6M Leistung:
-59.18%
1J Leistung:
+5.26%
1-Tages-Spanne:
$2.01
$2.225
1-Wochen-Bereich:
$1.78
$2.225
52-Wochen-Spanne:
$1.61
$6.88
Compass Therapeutics Inc Stock (CMPX) Company Profile
Firmenname
Compass Therapeutics Inc
Sektor
Branche
Telefon
617-500-8099
Adresse
80 GUEST STREET, BOSTON
Compare CMPX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
2.20 | 372.78M | 850.00K | -68.17M | -53.29M | -0.4116 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-13 | Eingeleitet | Craig Hallum | Buy |
| 2026-01-05 | Eingeleitet | William Blair | Outperform |
| 2025-12-03 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-12-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-12-03 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-07-01 | Fortgesetzt | Raymond James | Outperform |
| 2025-04-02 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-02-24 | Eingeleitet | Guggenheim | Buy |
| 2025-02-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-12-23 | Eingeleitet | D. Boral Capital | Buy |
| 2024-11-15 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-09-16 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2023-01-31 | Eingeleitet | Jefferies | Buy |
| 2023-01-27 | Eingeleitet | Stifel | Buy |
| 2022-05-23 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-03-15 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2022-01-19 | Eingeleitet | B. Riley Securities | Buy |
| 2021-12-22 | Eingeleitet | Raymond James | Outperform |
| 2021-12-20 | Eingeleitet | SVB Leerink | Outperform |
| 2021-12-15 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Compass Therapeutics Inc Aktie (CMPX) Neueste Nachrichten
Compass Therapeutics reports phase 1 data for CTX-8371 By Investing.com - Investing.com South Africa
Compass Therapeutics reports phase 1 data for CTX-8371 - Investing.com UK
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting - Investing News Network
Compass Therapeutics Announces Promising Phase 1 Results for CTX-8371, Innovative Dual Checkpoint Blocker in Advanced Malignancies - Quiver Quantitative
Compass Therapeutics to Present Promising Phase 1 Clinical - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc.CMPX - PR Newswire
CMPX News | COMPASS THERAPEUTICS INC (NASDAQ:CMPX) - ChartMill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass ... - Caledonian Record
CMPX Stock Chart | COMPASS THERAPEUTICS INC (NASDAQ:CMPX) - ChartMill
Compass Therapeutics (CMPX) Reports Q1 2026 Net Loss of $18.3M - Insider Monkey
Compass Therapeutics (CMPX) price target decreased by 26.39% to 10.11 - MSN
5 Best NASDAQ Stocks Under $5 to Buy Right Now - Insider Monkey
Compass Therapeutics(CMPX) Stock Options Chain | Quotes & News - Moomoo
Compass Therapeutics’s stock crashes after OS miss in BTC trial - MSN
Bronstein, Gewirtz & Grossman, LLC Is Investigating Compass Thera - The National Law Review
CMPX Technical Analysis | Trend, Signals & Chart Patterns | COMPASS THERAPEUTICS INC (NASDAQ:CMPX) - ChartMill
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Compass Therapeutics, Inc. (CMPX) And Encourages Shareholders to Reach Out - ACCESS Newswire
2026-05-13 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Compass Therapeutics, Inc. (CMPX) And Encourages Shareholders to Reach Out | NDAQ:CMPX | Press Release - Stockhouse
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - FinancialContent
TradingKey - TradingKey
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Compass Therapeutics, Inc. (CMPX) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
2026-05-12 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Compass Therapeutics, Inc. (CMPX) and Encourages Shareholders to Learn More About the Investigation | NDAQ:CMPX | Press Release - Stockhouse
Compass Therapeutics to Participate in Upcoming May Investor Events - The Manila Times
Compass Therapeutics, Inc. (CMPX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
CMPX Stock Price, Quote & Chart | COMPASS THERAPEUTICS INC (NASDAQ:CMPX) - ChartMill
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Compass Therapeutics, Inc. (CMPX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Compass Therapeutics, Inc. (CMPX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
symbol__ Stock Quote Price and Forecast - CNN
Q3 EPS Forecast for Compass Therapeutics Lifted by Analyst - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Compass Therapeutics, Inc. (CMPX) And Encourages Investors to Connect - ACCESS Newswire
CCORF Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Guggenheim Remains a Buy on Compass Therapeutics (CMPX) - The Globe and Mail
Craig-Hallum Maintains Compass Therapeutics(CMPX.US) With Buy Rating - Moomoo
Bronstein, Gewirtz & Grossman, LLC Encourages Compass Therapeutics, Inc. (CMPX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Compass Therapeutics 4Q Research and Development Expenses $13.4M >CMPX - Moomoo
2026-05-06 | Bronstein, Gewirtz & Grossman, LLC Encourages Compass Therapeutics, Inc. (CMPX) Stockholders to Inquire about Securities Investigation | NDAQ:CMPX | Press Release - Stockhouse
Compass Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
2026-05-05 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Compass Therapeutics, Inc. (CMPX) and Encourages Investors to Learn More About the Investigation | NDAQ:CMPX | Press Release - Stockhouse
8-K: Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Updatemoomoo - Moomoo
Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update - Investing News Network
Canaccord Maintains Buy Rating on Compass Therapeutics (CMPX) - Insider Monkey
Compass Therapeutics, Inc. 1Q 2026: Revenue ($18.76M), EPS ($0.1) — 10-Q Summary - TradingView
CMPX: Q1 2026 net loss rose to $18.3M; tovecimig advanced with positive BTC data and FDA orphan status - TradingView
Compass Therapeutics Q1 net loss widens on higher R&D, G&A costs - TradingView
CMPX: Tovecimig achieved key clinical milestones in BTC, with strong cash reserves supporting future trials - TradingView
Compass Therapeutics reports strong Phase 2/3 r... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
Bronstein, Gewirtz & Grossman, LLC Is Investigating Compass Therapeutics, Inc. (CMPX) And Encourages Stockholders to Connect - ACCESS Newswire
Compass Therapeutics, Inc. (CMPX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Finanzdaten der Compass Therapeutics Inc-Aktie (CMPX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):